AP basis, net loss for the second quarter of 2012 was $3.578 billion, or $2.51 per share. These results included goodwill and other intangible asset impairment charges, acquisition-related net credits, divestiture-, restructuring- and litigation-related charges and amortization expense, of $3.817 billion or $2.68 per share. Adjusted net income for the second quarter of 2012, excluding these net charges, was $239 million, or $0.17 per share.
Guidance for Third Quarter and Full Year 2013The company estimates sales for the third quarter of 2013 in a range of $1.700 to $1.760 billion. The company estimates earnings on a GAAP basis in a range of $0.03 to $0.05 per share. Adjusted earnings, excluding acquisition- and restructuring-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.14 to $0.16 per share.
The company estimates sales for the full year 2013 in a range of $7.050 to $7.170 billion. The company estimates losses on a GAAP basis in a range of ($0.07) to ($0.01) per share. Adjusted earnings, excluding goodwill and intangible asset impairment charges, acquisition-, restructuring-, and litigation-related charges, divestiture-related net credits and amortization expense; are estimated in a range of $0.67 to $0.71 per share.
Conference Call InformationBoston Scientific management will be discussing these results with analysts on a conference call today at 8:00 a.m. (ET). The company will webcast the call to interested parties through its website: www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for approximately one year on the Boston Scientific website.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1
|SOURCE Boston Scientific Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. American Laboratory Trading Continues Steady Growth with Expansion in Boston2
. Affordable Scrum Training in Boston,MA by Conscires Agile Practices3
. Formedix CEO Invited to Speak at OpenClinica Global Conference in Boston4
. The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA5
. Verified Clinical Trials (VCT) Will Co-Present With SAFE-BioPharma At Bio-IT World April 10th In Boston, MA Exploring Identity Management In eClinical Trials6
. Boston Heart Diagnostics Awarded $450,000 in Tax Incentives from the Massachusetts Life Sciences Center7
. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit8
. R&D, Innovation Key to Success - Research Report on Varian Medical Systems, Inc., Boston Scientific Corporation, Stryker Corporation, St. Jude Medical, Inc., and Thermo Fischer Scientific Inc.9
. Boston College researchers unique nanostructure produces novel plasmonic halos10
. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2012 Financial Results on January 29th11
. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration